Skip to content
OpenCapital
Get started

Denali Therapeutics Inc. DNLI Other Research And Development Expense

Other Research And Development Expense at other companies

Celanese Corporation logo
Celanese CorporationCE
$0—
Corvex logo
Corvex MOVE
$899K+12.4%
Disc Medicine logo
Disc MedicineIRON
$2.17M+18.2%
TG Therapeutics logo
TG TherapeuticsTGTX
$43.52M+1.1%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$18.67M-34.4%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.49M+25.5%

Segments

By segment

See full
Therapeutics Segment$23.55M-30.7%

Other financials

Income statement

See full
Revenue-—
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×